A study of pancreatic cancer showed that the administration of a variant of suratadenoturev armed with p53 (OBP-702) oncolytic virotherapy facilitated the activation and expansion of CD8+TRM cells and enhanced anti-tumor immunity.706. The gene discussed is CD8A; the disease is neoplasm.